Vaccinia Virus B18R, His Tag, His 20 - Glu 351 (Accession # P25213), was produced in human 293 cells (HEK293) at ACROBiosystems.
Predicted N-terminus: His 20
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 40.3 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Vaccinia Virus B18R, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human IFN-α1a at 2 μg/mL (100 μL/well) can bind Vaccinia Virus B18R, His Tag (Cat. No. B1R-H52H6) with a linear range of 0.8-6 ng/mL (QC tested).
B18R is a type I interferon (IFN)-binding protein and it is encoded by the B18R open reading frame in the WR (Western Reserve) strain of vaccinia virus, which contains two Ig-like C2-type domains and one Ig-like V-type domain. B18R exists in a soluble and a membrane-bound form. As a type I IFN receptor, B18R counteracts the antiviral effects of host IFN-alpha/beta. Also, B18R acts as a soluble IFN-alpha receptor and thus inhibits the interaction between host IFN-alpha and its receptor.